Items where authors include "Peckham, D."
Up a levelArticle
Liew, F., Efstathiou, C. orcid.org/0000-0001-6125-8126, Fontanella, S. et al. (1457 more authors) (2024) Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25 (4). pp. 607-621. ISSN 1529-2908
Edwards, A.J., King, M.-F., Noakes, C.J. et al. (2 more authors) (2024) The Wells–Riley model revisited: Randomness, heterogeneity, and transient behaviours. Risk Analysis: an international journal. ISSN 0272-4332
Edwards, A.J., King, M.F., López-García, M. orcid.org/0000-0003-3833-8595 et al. (2 more authors) (2024) Assessing the effects of transient weather conditions on airborne transmission risk in naturally ventilated hospitals. Journal of Hospital Infection. ISSN 0195-6701
Lord, J.M., Veenith, T., Sullivan, J. et al. (1020 more authors) (2024) Accelarated immune ageing is associated with COVID-19 disease severity. Immunity & Ageing, 21. 6. ISSN 1742-4933
Lord, J.M., Veenith, T., Sullivan, J. et al. (1020 more authors) (2024) Accelarated immune ageing is associated with COVID-19 disease severity. Immunity & Ageing, 21. 6. ISSN 1742-4933
Taquet, M., Skorniewska, Z., Zetterberg, H. orcid.org/0000-0003-3930-4354 et al. (1262 more authors) (2023) Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury. Brain Communications, 6 (1). fcad357. ISSN 2632-1297
Taquet, M., Skorniewska, Z., Zetterberg, H. orcid.org/0000-0003-3930-4354 et al. (1262 more authors) (2023) Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury. Brain Communications, 6 (1). fcad357. ISSN 2632-1297
Elneima, O. orcid.org/0000-0003-2480-8840, McAuley, H.J.C. orcid.org/0000-0001-8997-0764, Leavy, O.C. et al. (1398 more authors) (2023) Cohort profile: post-hospitalisation COVID-19 (PHOSP-COVID) study. International Journal of Epidemiology. ISSN 0300-5771
Brightling, C.E., Evans, R.A., Singapuri, A. et al. (1049 more authors) (2023) Long COVID research: an update from the PHOSP-COVID Scientific Summit. The Lancet Respiratory Medicine, 11 (11). e93-e94. ISSN 2213-2600
Raman, B., McCracken, C., Cassar, M.P. et al. (1038 more authors) (2023) Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study. The Lancet Respiratory Medicine, 11 (11). pp. 1003-1019. ISSN 2213-2600
Sellers, Z.M., Assis, D.N., Paranjape, S.M. et al. (20 more authors) (2023) Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations. Hepatology. ISSN 0270-9139
Jackson, C., Stewart, I.D., Plekhanova, T. et al. (1082 more authors) (2023) Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. The Lancet Respiratory Medicine, 11 (8). pp. 673-684. ISSN 2213-2600
Zheng, B., Vivaldi, G. orcid.org/0000-0003-0816-9276, Daines, L. orcid.org/0000-0003-0564-4000 et al. (1040 more authors) (2023) Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls. The Lancet Regional Health - Europe, 29. 100635. ISSN 2666-7762
Zheng, B., Vivaldi, G. orcid.org/0000-0003-0816-9276, Daines, L. orcid.org/0000-0003-0564-4000 et al. (1040 more authors) (2023) Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls. The Lancet Regional Health - Europe, 29. 100635. ISSN 2666-7762
Uluer, A.Z., MacGregor, G., Azevedo, P. et al. (103 more authors) (2023) Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. The Lancet Respiratory Medicine, 11 (6). pp. 550-562. ISSN 2213-2600
Tachtatzis, P., Spoletini, G. orcid.org/0000-0002-5462-0083, Clifton, I. orcid.org/0000-0002-9758-9506 et al. (2 more authors) (2023) Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and liver transplant. Journal of Cystic Fibrosis. ISSN 1569-1993
Mainz, J.G., Zagoya, C., Polte, L. et al. (12 more authors) (2023) Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score. Frontiers in Pharmacology, 14. 1207356. ISSN 1663-9812
Jackson, C., Stewart, I.D., Plekhanova, T. et al. (1082 more authors) (2023) Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. The Lancet Respiratory Medicine. ISSN 2213-2600
Calthorpe, R.J. orcid.org/0000-0003-3676-2712, Goodchild, N., Gleetus, V. et al. (10 more authors) (2023) A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era. NIHR Open Research, 3. 18. ISSN 2633-4402
Liew, F. orcid.org/0000-0002-8736-9198, Talwar, S., Cross, A. et al. (1439 more authors) (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine, 87. 104402. ISSN 2352-3964
Archangelidi, O., Cullinan, P., Simmonds, N.J. et al. (4 more authors) (2022) Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. Journal of Cystic Fibrosis, 21 (2). pp. 302-308. ISSN 1569-1993
Sutharsan, S., McKone, E.F., Downey, D.G. et al. (51 more authors) (2022) Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. The Lancet Respiratory Medicine, 10 (3). pp. 267-277. ISSN 2213-2600
Conference or Workshop Item
Shaw, N. orcid.org/0000-0003-3221-2588, Alldred, D., Anderson, A. et al. (4 more authors) (2023) Medication burden among adults with cystic fibrosis prescribed CFTR Modulators: a cross-sectional survey. In: 46th European Cystic Fibrosis Society Conference, 07-10 Jun 2023, Vienna.
Proceedings Paper
Baxter, G., Pakzad, A., Rangelov, B. et al. (5 more authors) (2023) Quantitative computed tomography measures of disease severity in cystic fibrosis. In: ERJ Open Research. Adult Cystic Fibrosis Conference, 2023, 01-02 Dec 2023, Milan, Italy. European Respiratory Society .
Watson, R., Marner, B., Sum, C.K. et al. (2 more authors) (2023) Feasibility and effectiveness of a low-impact, virtual exercise programme for adults with cystic fibrosis. In: Journal of Cystic Fibrosis. 46th European Cystic Fibrosis Conference, 07-10 Jun 2023, Vienna, Austria. Elsevier , S196-S196.
Tachtatzis, P., Spoletini, G., Etherington, C. et al. (2 more authors) (2022) OP31 Can liver biopsy guide the management of deranged liver function tests in liver transplant recipients receiving Kaftrio? In: Gut. British Association for the Study of the Liver Annual Meeting, 20–23 September 2022, 20-23 Sep 2022, Leeds, United Kingdom. BMJ Publishing Group , A27-A28.
Shires, M. orcid.org/0000-0003-0904-6200, Marks, K., Peckham, D. orcid.org/0000-0001-7723-1868 et al. (1 more author) (2020) Sa1092 APICAL BK CHANNELS IN INTESTINAL EPITHELIA OF CYSTIC FIBROSIS (CF) PATIENTS: A POTENTIAL TARGET FOR STIMULATING POTASSIUMDRIVEN WATER SECRETION. In: Gastroenterology. Digestive Disease Week (DDW) 2020, 02-05 May 2020, Chicago, USA. Elsevier , S272-S273.